Stock Market Reviews

BIIB (Biogen Inc.) News

Get the latest news, insights, and market updates on BIIB (Biogen Inc.). Explore the news page 4 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List
  TOKYO and CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that anti-Aβ protofibril* antibody “LEQEMBI®” (brand name in China: “乐意保®”, generic name: lecanemab), has been included in the “Commercial Insurance Innovative Drug List” (Chinese: 商业健康保险创新药品目录), recently introduced by the National He
  Dec 8, 2025 - $BIIB
• Is New Neurology Data And Partnerships Altering The Investment Case For Biogen (BIIB)?
  In late November and early December 2025, Biogen and its partners Eisai, Stoke Therapeutics and Dayra Therapeutics reported new clinical data and collaborations spanning Alzheimer’s disease, Dravet syndrome and oral macrocyclic peptide research, including positive updates on lecanemab’s subcutaneous formulation and zorevunersen’s long-term effects. The latest findings suggest Biogen is deepening its presence in high-need neurological conditions with therapies that aim not only to relieve...
  Dec 7, 2025 - $BIIB
• Revolution Medicines (RVMD) Up 27.9% Since Last Earnings Report: Can It Continue?
  Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
  Dec 5, 2025 - $BIIB
• Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
  —Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in seizure-free days, in addition to improvements in cognition, behavior and quality of life— —Propensity score weighted analysis comparing the effects of zorevunersen to natural history showed reductions in seizures and improvements in cognition and behavior with dose levels and timepoints similar to and c
  Dec 5, 2025 - $BIIB
• Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
  BEDFORD, Mass. & CAMBRIDGE, Mass., December 05, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced data presentations that further support the potential of zorevunersen, an investigational antisense oligonucleotide, as a disease-modifying medicine for Dravet syndrome. These data were presented at the 2025 American Epilepsy Society (AES
  Dec 5, 2025 - $BIIB
• Why Is Myriad (MYGN) Up 8.7% Since Last Earnings Report?
  Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
  Dec 3, 2025 - $BIIB
• Tech Is Getting Left Behind in the S&P 500’s Latest Rebound
  Eli Lilly & Co, Cardinal Health Inc. and Biogen Inc. are among the top 10 performers in the S&P 500 since Oct. 28, the last time the index closed at a record. In contrast, the S&P 500 Information Technology index is down 4.2% since then, with bigger losses coming from Magnificent Seven stocks like Nvidia Corp. and Microsoft Corp. The moves suggest that investor are still skittish about the artificial intelligence trade as concerns linger about valuations and whether all the heavy spending on computing power will pay off with profits.
  Dec 3, 2025 - $BIIB
• Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025
  Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate Alzheimer’s disease by up to 8.3 years in low-amyloid group who started treatment at an early stage New safety and efficacy data presented at scientific symposium on subcutaneous formulation for LEQEMBI initiation treatment, which is under regulatory review in the United States TOKYO and CAMBRIDGE, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tok
  Dec 3, 2025 - $BIIB
• Biogen (BIIB): Assessing Valuation After Recent Share Price Gains
  Biogen (BIIB) shares have been actively discussed lately, as some investors weigh the stock's longer-term track record against recent performance. Over the past month, Biogen stock has climbed by 15%, which is higher compared to its returns from earlier periods. See our latest analysis for Biogen. Momentum has picked up for Biogen lately, with a 15% one-month share price return and year-to-date gains of 18%, signaling renewed optimism after a tough few years. Still, its 1-year total...
  Dec 2, 2025 - $BIIB
• Pre-filled Syringe Presentation of BYOOVIZ®, Samsung Bioepis' Biosimilar to Lucentis (Ranibizumab), Gains European Approval
  INCHEON, Korea, December 02, 2025--Samsung Bioepis' Byooviz PFS gains European approval.
  Dec 2, 2025 - $BIIB